Tag:
zalutumumab
Latest Headlines
Latest Headlines
Genmab drops zalutumumab
Genmab has shelved zalutumumab, a drug for squamous cell carcinoma of the head and neck, to focus on other drugs in its pipeline. The developer announced last year that it would hunt for a partner to
Genmab will look to U.S. partner to push PhIII zalutumumab work
Emboldened by recent talks with regulators, Denmark's Genmab says its cancer drug zalutumumab looks like its nearing the point at which it can be filed for an approval in Europe. But it looks like
Genmab shares spike on fresh rumors of a Glaxo takeover
A little fresh speculation regarding some old talk about a possible GlaxoSmithKline takeover of Genmab inspired a spike in the Denmark developer's share price. "The stock value is so low it makes
